{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T10:44:06Z","timestamp":1772275446022,"version":"3.50.1"},"reference-count":60,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Demand for donor kidneys outstrips supply. Using kidneys from selected donors with an increased risk of blood-borne virus (BBV) transmission (hepatitis B virus and hepatitis C virus [HCV], human immunodeficiency virus) may expand the donor pool, but cost-effectiveness of this strategy is uncertain.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>A Markov model was developed using real-world evidence to compare healthcare costs and quality-adjusted life years (QALYs) of accepting kidneys from deceased donors with potential increased risk of BBV transmission, because of increased risk behaviors and\/or history of HCV, versus declining these kidneys. Model simulations were run over a 20-y time horizon. Parameter uncertainty was assessed through deterministic and probabilistic sensitivity analyses.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>Accepting kidneys from donors at increased risk of BBVs (2% from donors with increased-risk behaviors and 5% from donors with active or past HCV infection) incurred total costs of 311\u2009303 Australian dollars with a gain of 8.53 QALYs. Foregoing kidneys from these donors incurred total costs of $330\u2009517 and a gain of 8.44 QALYs. A cost-saving of $19\u2009214 and additional 0.09 QALYs (~33 d in full health) per person would be generated compared with declining these donors. Increasing the availability of kidneys with increased risk by 15% led to further cost-savings of $57\u2009425 and additional 0.23 QALY gains (~84 d in full health). Probabilistic sensitivity analysis using 10\u2009000 iterations showed accepting kidneys from donors at increased risk led to lower costs and higher QALY gains.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>Shifting clinical practice to accept increased BBV risk donors would likely produce lower costs and higher QALYs for health systems.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000004632","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T04:00:26Z","timestamp":1684728026000},"page":"2028-2042","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Cost-effectiveness of Kidney Transplantation From Donors at Increased Risk of Blood-borne Virus Infection Transmission"],"prefix":"10.1097","volume":"107","author":[{"given":"Karan K.","family":"Shah","sequence":"first","affiliation":[{"name":"Health Economics and Health Technology Assessment, NHMRC Clinical Trials Centre, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Wyld","sequence":"additional","affiliation":[{"name":"Collaborative Centre for Organ Donation Evidence, Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia."},{"name":"Centre for Transplant and Renal Research, Westmead Hospital, Sydney, NSW, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James A.","family":"Hedley","sequence":"additional","affiliation":[{"name":"Collaborative Centre for Organ Donation Evidence, Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen M.J.","family":"Waller","sequence":"additional","affiliation":[{"name":"Collaborative Centre for Organ Donation Evidence, Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"De La Mata","sequence":"additional","affiliation":[{"name":"Collaborative Centre for Organ Donation Evidence, Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela C.","family":"Webster","sequence":"additional","affiliation":[{"name":"Health Economics and Health Technology Assessment, NHMRC Clinical Trials Centre, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia."},{"name":"Collaborative Centre for Organ Donation Evidence, Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia."},{"name":"Centre for Transplant and Renal Research, Westmead Hospital, Sydney, NSW, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachael L.","family":"Morton","sequence":"additional","affiliation":[{"name":"Health Economics and Health Technology Assessment, NHMRC Clinical Trials Centre, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,8,21]]},"reference":[{"key":"R1-20250604","doi-asserted-by":"crossref","first-page":"e1001307","DOI":"10.1371\/journal.pmed.1001307","article-title":"A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments.","volume":"9","author":"Wyld","year":"2012","journal-title":"PLoS Med"},{"key":"R2-20250604","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1111\/j.1600-6143.2011.03686.x","article-title":"Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes.","volume":"11","author":"Tonelli","year":"2011","journal-title":"Am J Transplant"},{"key":"R3-20250604","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40258-020-00614-4","article-title":"The cost-effectiveness of kidney replacement therapy modalities: a systematic review of full economic evaluations.","volume":"19","author":"Yang","year":"2021","journal-title":"Appl Health Econ Health Policy"},{"key":"R4-20250604","doi-asserted-by":"crossref","first-page":"100585","DOI":"10.1016\/j.trre.2020.100585","article-title":"Organ donation in the US and Europe: the supply vs demand imbalance.","volume":"35","author":"Lewis","year":"2021","journal-title":"Transplant Rev (Orlando)"},{"key":"R5-20250604","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/TP.0000000000001885","article-title":"Hepatitis Transmission Risk in Kidney Transplantation (the HINT study): a cross-sectional survey of transplant clinicians in Australia and New Zealand.","volume":"102","author":"Waller","year":"2018","journal-title":"Transplantation"},{"issue":"Suppl 2","key":"R7-20250604","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/ajt.16982","article-title":"OPTN\/SRTR 2020 annual data report: kidney.","volume":"22","author":"Lentine","year":"2022","journal-title":"Am J Transplant"},{"key":"R8-20250604","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.34067\/KID.0002472021","article-title":"Global perspective on kidney transplantation: United States.","volume":"2","author":"Wang","year":"2021","journal-title":"Kidney360"},{"key":"R9-20250604","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1093\/ndt\/gfy390","article-title":"How to increase kidney transplant activity throughout Europe\u2014An advocacy review by the European Kidney Health Alliance.","volume":"34","author":"Vanholder","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"R12-20250604","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/TP.0000000000003715","article-title":"Characteristics and donation outcomes of potential organ donors perceived to be at increased risk for blood borne virus transmission: an Australian Cohort Study 2010-2018.","volume":"106","author":"Waller","year":"2022","journal-title":"Transplantation"},{"key":"R14-20250604","doi-asserted-by":"crossref","first-page":"e782","DOI":"10.1097\/TXD.0000000000001238","article-title":"The 3-T model of informed consent for nonstandard risk donors: a proposal for transplant clinical practice.","volume":"7","author":"Grossi","year":"2021","journal-title":"Transplant Direct"},{"key":"R15-20250604","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1097\/TP.0000000000001673","article-title":"The \u201cPHS Increased Risk\u201d label is associated with nonutilization of hundreds of organs per year.","volume":"101","author":"Volk","year":"2017","journal-title":"Transplantation"},{"key":"R16-20250604","doi-asserted-by":"crossref","first-page":"414","DOI":"10.5694\/mja2.50315","article-title":"Residual risk of infection with blood\u2010borne viruses in potential organ donors at increased risk of infection: systematic review and meta\u2010analysis.","volume":"211","author":"Waller","year":"2019","journal-title":"Med J Aust"},{"key":"R17-20250604","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.","volume":"384","author":"Lawitz","year":"2014","journal-title":"The Lancet"},{"key":"R18-20250604","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/M17-2871","article-title":"Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to noninfected recipients: an open-label nonrandomized trial.","volume":"168","author":"Durand","year":"2018","journal-title":"Ann Intern Med"},{"key":"R19-20250604","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMc1705221","article-title":"Trial of transplantation of HCV-infected kidneys into uninfected recipients.","volume":"376","author":"Goldberg","year":"2017","journal-title":"N Eng J Med"},{"key":"R20-20250604","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ekir.2021.11.022","article-title":"One-Year Outcomes of the Multi-Center StudY to Transplant Hepatitis C-InfeCted kidneys (MYTHIC) Trial.","volume":"7","author":"Sise","year":"2022","journal-title":"Kidney Int Rep"},{"key":"R21-20250604","doi-asserted-by":"crossref","first-page":"273","DOI":"10.7326\/M18-0749","article-title":"Twelve-month outcomes after transplant of hepatitis C-infected kidneys into uninfected recipients: a single-group trial.","volume":"169","author":"Reese","year":"2018","journal-title":"Ann Intern Med"},{"key":"R22-20250604","doi-asserted-by":"crossref","first-page":"109","DOI":"10.7326\/M16-1205","article-title":"Treatment with ledipasvir\u2013sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial.","volume":"166","author":"Colombo","year":"2017","journal-title":"Ann Intern Med"},{"key":"R23-20250604","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1097\/QAD.0000000000002518","article-title":"Organ transplantation in persons with HIV.","volume":"34","author":"Kumar","year":"2020","journal-title":"AIDS"},{"key":"R24-20250604","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-58215-z","article-title":"Cost-effectiveness of transplanting lungs and kidneys from donors with potential hepatitis C exposure or infection.","volume":"10","author":"Scott","year":"2020","journal-title":"Sci Rep"},{"key":"R25-20250604","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/ajt.15054","article-title":"Cost-effectiveness of hepatitis C-positive donor kidney transplantation for hepatitis C-negative recipients with concomitant direct\u2010acting antiviral therapy.","volume":"18","author":"Gupta","year":"2018","journal-title":"Am J Transplant"},{"key":"R26-20250604","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1111\/ajt.14929","article-title":"Cost\u2010effectiveness of using kidneys from hepatitis C nucleic acid test-positive donors for transplantation in hepatitis C-negative recipients.","volume":"18","author":"Kadatz","year":"2018","journal-title":"Am J Transplant"},{"key":"R27-20250604","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1097\/TP.0000000000002033","article-title":"Use of organs from hepatitis C virus-positive donors for uninfected recipients: a potential cost-effective approach to save lives?","volume":"102","author":"Trotter","year":"2018","journal-title":"Transplantation"},{"key":"R28-20250604","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1053\/j.ajkd.2019.11.005","article-title":"Cost-effectiveness of using kidneys from HCV-viremic donors for transplantation into HCV-uninfected recipients.","volume":"75","author":"Eckman","year":"2020","journal-title":"Am J Kid Dis"},{"key":"R29-20250604","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3350\/cmh.2021.0137","article-title":"Cost-effectiveness and long-term outcomes of liver transplantation using hepatitis B core antibody-positive grafts with hepatitis B immunoglobulin prophylaxis in Korea.","volume":"27","author":"Kim","year":"2021","journal-title":"Clin Mol Hepatol"},{"key":"R30-20250604","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/bmb\/ldq033","article-title":"Health outcomes in economic evaluation: the QALY and utilities.","volume":"96","author":"Whitehead","year":"2010","journal-title":"Br Med Bull"},{"key":"R32-20250604","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1111\/j.1523-1755.2004.00950.x","article-title":"Acceptance and rejection: cost-effectiveness and the working nephrologist.","volume":"66","author":"McFarlane","year":"2004","journal-title":"Kidney Int"},{"key":"R33-20250604","doi-asserted-by":"crossref","first-page":"e067975","DOI":"10.1136\/bmj-2021-067975","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.","volume":"376","author":"Husereau","year":"2022","journal-title":"BMJ"},{"key":"R34-20250604","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/nep.13484","article-title":"Access to waitlisting for deceased donor kidney transplantation in Australia.","volume":"24","author":"Sypek","year":"2019","journal-title":"Nephrology (Carlton)"},{"key":"R36-20250604","doi-asserted-by":"crossref","first-page":"e13437","DOI":"10.1111\/tid.13437","article-title":"New blood\u2010borne virus infections among organ transplant recipients: an Australian data\u2010linked cohort study examining donor transmissions and other HIV, hepatitis C and hepatitis B notifications, 2000\u20102015.","volume":"22","author":"Waller","year":"2020","journal-title":"Transpl Infect Dis"},{"key":"R37-20250604","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1111\/jgh.13679","article-title":"Assessing the clinical and economic impact of increasing treatment uptake in chronic hepatitis B infection using a Markov model.","volume":"32","author":"Chinnaratha","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"key":"R38-20250604","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/jvh.13252","article-title":"Enhancing the hepatitis B care cascade in Australia: a cost\u2010effectiveness model.","volume":"27","author":"Xiao","year":"2020","journal-title":"J Viral Hep"},{"key":"R39-20250604","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1097\/MEG.0000000000001659","article-title":"Cost effectiveness of treatment models of care for hepatitis C: the South Australian state-wide experience.","volume":"32","author":"Ramachandran","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R42-20250604","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/imj.12797","article-title":"Cost to government and society of chronic kidney disease stage 1\u20135: a national cohort study.","volume":"45","author":"Wyld","year":"2015","journal-title":"Int Med J"},{"key":"R43-20250604","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1093\/cid\/cit946","article-title":"A cost-effectiveness analysis of HIV preexposure prophylaxis for men who have sex with men in Australia.","volume":"58","author":"Schneider","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R48-20250604","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/j.ekir.2020.09.028","article-title":"Health-related quality of life in people across the spectrum of CKD.","volume":"5","author":"Krishnan","year":"2020","journal-title":"Kidney Int Rep"},{"key":"R49-20250604","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/jgh.13223","article-title":"Cost\u2010effectiveness of treating chronic hepatitis C virus with direct\u2010acting antivirals in people who inject drugs in Australia.","volume":"31","author":"Scott","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"R50-20250604","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/S2352-3018(14)70018-9","article-title":"Health-related quality-of-life of people with HIV in the era of combination antiretroviral treatment: a cross-sectional comparison with the general population.","volume":"1","author":"Miners","year":"2014","journal-title":"Lancet HIV"},{"key":"R52-20250604","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1111\/ajt.13518","article-title":"Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation.","volume":"16","author":"Kamar","year":"2016","journal-title":"Am J Transplant"},{"key":"R53-20250604","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1097\/TP.0000000000002033","article-title":"Use of organs from hepatitis C virus-positive donors for uninfected recipients: a potential cost-effective approach to save lives?","volume":"102","author":"Trotter","year":"2018","journal-title":"Transplantation"},{"key":"R54-20250604","doi-asserted-by":"crossref","first-page":"e13427","DOI":"10.1111\/ctr.13427","article-title":"Outcomes for potential kidney transplant recipients offered Public Health Service increased risk kidneys: a single-center experience.","volume":"32","author":"Fernandez","year":"2018","journal-title":"Clin Transplant"},{"key":"R55-20250604","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/ajt.12206","article-title":"Identifying appropriate recipients for CDC infectious risk donor kidneys.","volume":"13","author":"Chow","year":"2013","journal-title":"Am J Transplant"},{"key":"R56-20250604","doi-asserted-by":"crossref","first-page":"61","DOI":"10.15585\/mmwr.mm6803a2","article-title":"Characteristics of deceased solid organ donors and screening results for hepatitis B, C, and human immunodeficiency viruses\u2014United States, 2010\u20132017.","volume":"68","author":"Abara","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R58-20250604","first-page":"2","article-title":"Deceased donor characteristics and kidney transplant outcomes.","volume":"2022","author":"Sharif","year":"1048","journal-title":"Transpl Int"},{"key":"R59-20250604","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/MOT.0000000000000735","article-title":"Increased-risk donors and solid organ transplantation: current practices and opportunities for improvement.","volume":"25","author":"Brown","year":"2020","journal-title":"Curr Opin Organ Transplant"},{"key":"R60-20250604","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet (London, England)"},{"key":"R61-20250604","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2007.11.011","article-title":"Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors.","volume":"48","author":"Fattovich","year":"2008","journal-title":"J Hepatol"},{"key":"R62-20250604","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/liv.13142","article-title":"Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis.","volume":"36","author":"Raffetti","year":"2016","journal-title":"Liver Int"},{"key":"R63-20250604","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1136\/gutjnl-2015-309892","article-title":"Natural history of chronic HBV infection in West Africa: a longitudinal population-based study from The Gambia.","volume":"65","author":"Shimakawa","year":"2016","journal-title":"Gut"},{"key":"R64-20250604","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/MEG.0000000000000341","article-title":"Rates of cirrhosis and hepatocellular carcinoma in chronic hepatitis B and the role of surveillance: a 10-year follow-up of 673 patients.","volume":"27","author":"Poh","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R65-20250604","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/hep.26301","article-title":"Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis.","volume":"58","author":"Wong","year":"2013","journal-title":"Hepatology"},{"key":"R66-20250604","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s10620-009-0747-y","article-title":"Factors associated with progression to hepatocellular carcinoma and to death from liver complications in patients with HBsAg-positive cirrhosis.","volume":"54","author":"Tong","year":"2009","journal-title":"Dig Dis Sci"},{"key":"R67-20250604","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jhep.2009.11.007","article-title":"Efficacy of entecavir in treatment-na\u00efve patients with hepatitis B virus-related decompensated cirrhosis.","volume":"52","author":"Shim","year":"2010","journal-title":"J Hepatol"},{"key":"R68-20250604","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1053\/j.gastro.2014.02.033","article-title":"Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine.","volume":"147","author":"Lim","year":"2014","journal-title":"Gastroenterology"},{"key":"R69-20250604","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/liv.13966","article-title":"Hepatocellular carcinoma in Australia 1982-2014: increasing incidence and improving survival.","volume":"39","author":"Wallace","year":"2019","journal-title":"Liver Int"},{"key":"R70-20250604","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1002\/hep.29399","article-title":"Modeling cost\u2010effectiveness and health gains of a \u201cuniversal\u201d versus \u201cprioritized\u201d hepatitis C virus treatment policy in a real\u2010life cohort.","volume":"66","author":"Kondili","year":"2017","journal-title":"Hepatology"},{"key":"R71-20250604","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1681\/ASN.2020050566","article-title":"Death after kidney transplantation: an analysis by era and time post-transplant.","volume":"31","author":"Ying","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"R72-20250604","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1136\/gut.2005.064774","article-title":"Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C.","volume":"55","author":"Grieve","year":"2006","journal-title":"Gut"},{"key":"R73-20250604","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta10210","article-title":"Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation.","volume":"10","author":"Wright","year":"2006","journal-title":"Health Technol Assess"},{"key":"R74-20250604","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11110","article-title":"Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation.","volume":"11","author":"Shepherd","year":"2007","journal-title":"Health Technol Assess"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004632","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T18:11:50Z","timestamp":1749060710000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,21]]},"references-count":60,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000004632","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,21]]}}}